Talking Medicines targets growing demand for GLP-1 patient intelligence

Tern plc

Talking Medicines is using consumer conversations around GLP-1 weight-loss plateaus to show how behavioural data can help life sciences companies better understand patients, treatment expectations and communication needs.

The company’s analysis found that many consumers do not automatically see a weight-loss plateau as treatment failure. Instead, they discuss practical responses such as changing exercise habits, improving hydration and considering dose adjustments. These conversations also show patients actively comparing experiences and seeking advice from others.

Patient behaviour can affect adherence, expectations and the way treatment is perceived over time. For pharmaceutical companies, understanding these shifts can help improve patient education, support programmes and communication strategies.

Talking Medicines describes this trend as informed consumerisation. Patients are becoming more active in treatment decisions and are using online information and peer experiences to shape their views. That creates demand for tools that can capture and interpret what patients are saying outside traditional clinical settings.

The company’s analysis also found that attitudes can change as treatment progresses. Early focus on rapid weight loss may move towards maintenance, tolerance and longer-term lifestyle goals. Consumers also discuss frustration, motivation and uncertainty, showing that emotional responses can influence how they view treatment.

Dose stability, side effects and medication tolerance become more important as treatment continues. These factors can affect whether patients remain engaged and how they respond to medical or commercial messaging.

Talking Medicines’ DrugVoice platform converts unstructured healthcare conversations into behavioural intelligence. The aim is to help life sciences companies understand not only what patients are saying, but why attitudes and behaviours may be changing.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Tern invests £78,000 in Device Authority through 8% convertible loan notes

Tern Plc has committed approximately £78,000 to new convertible loan notes issued by Device Authority, which carry 8% annual...

Search